MLN3126|cas:628300-71-0|西域试剂

MLN3126,98.64%

产品编号：Bellancom-123763| CAS NO：628300-71-0| 分子式：C₂₁H₁₉ClN₂O₅S| 分子量：446.90

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-123763	￥2250.00	杭州北京（现货）
Bellancom-123763	￥3600.00	杭州北京（现货）
Bellancom-123763	￥7650.00	杭州北京（现货）
Bellancom-123763	￥12150.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MLN3126

产品介绍

MLN3126 是一种具有口服活性的强效 CCR9 拮抗剂。 MLN3126 抑制 CCL25 诱导的钙动员 (calcium mobilization) 和小鼠初级胸腺细胞趋化 (chemotaxis)，抑制钙内流的 IC₅₀ 为 6.3 nM。

生物活性

MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx.

体外研究

MLN3126 inhibits CCL25-induced calcium mobilization with an IC₅₀ value of 6.3 nM in CCR9 expressing cells.
MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC₅₀ of 14.2 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Invasion Assay

Cell Line:	Mouse thymocytes
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	90 min
Result:	Inhibited CCL25-induced chemotaxis of mouse thymocytes.

体内研究
(In Vivo)

MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells.
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Activated T cell transferred colitis mouse model
Dosage:	0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:	Oral gavage; 21 days
Result:	Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Activated T cell transferred colitis mouse model
Dosage:	0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:	Oral gavage; 21 days
Result:	Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Activated T cell transferred colitis mouse model
Dosage:	0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:	Oral gavage; 21 days
Result:	Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (55.94 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2376 mL	11.1882 mL	22.3764 mL
5 mM	0.4475 mL	2.2376 mL	4.4753 mL
10 mM	0.2238 mL	1.1188 mL	2.2376 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式